Corcept Faces Appellate Setback in Korlym Patent Dispute

Corcept Therapeutics ( (CORT) ) just unveiled an update.

On February 19, 2026, Corcept Therapeutics announced that the U.S. Court of Appeals for the Federal Circuit ruled Teva Pharmaceuticals’ marketing of a generic version of Korlym does not infringe two Corcept patents covering methods of safely co-administering Korlym with CYP3A4-inhibiting drugs commonly used by patients with Cushing’s syndrome. The decision upholds a December 2023 verdict from the Federal District Court for the District of New Jersey, potentially clearing a key legal hurdle for Teva’s generic Korlym product and raising competitive and revenue implications for Corcept’s flagship hypercortisolism therapy.

Corcept’s chief executive officer, Joseph K. Belanoff, M.D., expressed disappointment with the ruling, emphasizing that the asserted patents protect treatment methods relied on daily by physicians treating Cushing’s syndrome. He stated that the company will vigorously defend its intellectual property rights and is evaluating options for further judicial review, signaling an ongoing legal strategy as Corcept seeks to protect market exclusivity and manage the impact of generic competition on its Korlym franchise.

The most recent analyst rating on (CORT) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Spark’s Take on CORT Stock

According to Spark, TipRanks’ AI Analyst, CORT is a Neutral.

The score is primarily supported by strong financial health (very low leverage, solid ROE, high gross margin) and constructive business momentum from guidance and pipeline progress. These positives are meaningfully offset by very weak technical trend signals (price far below major moving averages) and profitability/cash-flow pressure, with valuation (high P/E) and mixed regulatory outcomes adding risk.

To see Spark’s full report on CORT stock, click here.

More about Corcept Therapeutics

Corcept Therapeutics, based in Redwood City, Calif., is a commercial-stage biopharmaceutical company focused on discovering and developing medications that modulate the hormone cortisol to treat severe endocrinologic, oncologic, metabolic and neurologic disorders. The company has developed more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists and markets Korlym, the first FDA-approved treatment for patients with endogenous hypercortisolism, while conducting advanced clinical trials in hypercortisolism, solid tumors, ALS and liver disease.

For over 25 years, Corcept has concentrated on cortisol modulation as its core scientific and commercial strategy, targeting serious conditions where excess cortisol plays a key role in disease progression. Its primary market focus includes patients with Cushing’s syndrome and related hypercortisolism disorders, as well as broader applications in oncology and other systemic diseases where cortisol signaling is implicated.

Average Trading Volume: 1,904,607

Technical Sentiment Signal: Sell

Current Market Cap: $4.17B

Learn more about CORT stock on TipRanks’ Stock Analysis page.